Compare Natera Inc. Common Stock (NTRA) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Natera Inc. Common Stock trades at $393.93 (market cap $57.03B), while Vanguard Dividend Appreciation Index Fund ETF trades at $239.98 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 2.3× Natera Inc. Common Stock's market cap, and Vanguard Dividend Appreciation Index Fund ETF is more actively traded (893,381 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Dividend Appreciation Index Fund ETF for 134 Days on average.
| NTRA | VIG | |
|---|---|---|
Market Cap | $57.03B | $132.40B |
Volume | 1,131,157 | 893,381 |
Sector | Health | — |
52-Week High | $425.64 | $246.61 |
52-Week Low | $179.42 | $210.70 |
Typical Hold Time | 0 Days | 134 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VIG trades at $239.71, down slightly by 0.14% on the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF focuses on dividend growth stocks with a requirement for 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights VIG's 7.5% quarterly dividend increase and its strategic exclusion of high-yield stocks to prioritize sustainable growth.
The outlook for VIG remains positive given its quality dividend growth strategy and historical 10% annual returns, though the current RSI near 90 suggests short-term overbought conditions. Key risks include sensitivity to interest rate changes and slower dividend growth rates. Analyst sentiment is generally favorable, emphasizing VIG's role in long-term wealth building despite its modest yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
